Dr. Levin is the Chairman and CEO of Ovid Therapeutics, Inc., a public company developing novel medicines to treat rare diseases of the brain.
Prior to Ovid, Dr. Levin served as President and CEO of Teva Pharmaceutical Industries Ltd., the world’s largest generics drug company. Previously, he was a member of the Executive Committee of Bristol-Myers Squibb, where he devised and led the “String of Pearls” strategy that resulted in the transformation of the company. Prior to BMS, he was Global Head of Strategic Alliances at Novartis and established and managed strategic collaborations with companies around the world. Dr. Levin has served on a number of public and private company boards over the years. He is currently the Chairman of the Board at Ophtea; a member of the Board of Directors for Lundbeck, and a member of the Board of Directors for the Biotechnology Innovation Organization (BIO), for which he is the immediate past chairman.
Dr. Levin has been awarded the Kermode Prize for work on novel hypertension drugs, the Albert Einstein Award for Leadership in Life Sciences and the B’nai B’rith Award for Distinguished Achievement for commitment to improving global healthcare. Dr. Levin was voted as one of the 25 most influential biotechnology leaders by Fierce Biotech; one of the top 3 biotechnology CEOs by The Healthcare Technology Report; and one of the PharmaVoice100 CEOs in 2020.
Dr. Levin earned his BA (Hons) in Zoology First Class with University Prize, MA and DPhil in Chromatin Structure at the University of Oxford. He secured his MB and CHIR degrees from the University of Cambridge. He has practiced internal medicine at University Hospitals in England, Switzerland and South Africa.